CN118001370A - Compositions and methods for treating neurodegenerative diseases - Google Patents
Compositions and methods for treating neurodegenerative diseases Download PDFInfo
- Publication number
- CN118001370A CN118001370A CN202410424222.XA CN202410424222A CN118001370A CN 118001370 A CN118001370 A CN 118001370A CN 202410424222 A CN202410424222 A CN 202410424222A CN 118001370 A CN118001370 A CN 118001370A
- Authority
- CN
- China
- Prior art keywords
- seq
- composition
- polypeptide
- disease
- microglial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 18
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 33
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 230000002025 microglial effect Effects 0.000 claims abstract description 15
- 210000001808 exosome Anatomy 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 6
- 238000012347 Morris Water Maze Methods 0.000 abstract description 4
- 238000010172 mouse model Methods 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000823042 Mus musculus Amyloid-beta precursor protein Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application provides a composition for treating neurodegenerative diseases, wherein the composition takes a polypeptide which is derived from an M2 type microglial exosome and has an amino acid sequence of SEQ ID NO.1, SEQ ID NO.3 or SEQ ID NO.5 as an active ingredient. The composition of the application has better safety; the method has the advantages that the method shows more remarkable effects on Morris water maze test and serum GSH, SOD, A beta 1–42 level in a D-galactose mouse model. Provides a new potential drug choice for treating such diseases.
Description
Technical Field
The application belongs to the fields of cell biology, protein and neurodegenerative disease treatment, in particular to a composition and a method for treating neurodegenerative diseases.
Background
Neurodegenerative diseases, such as Alzheimer's disease, are frequently found in elderly patients. It is currently believed that the main causes of alzheimer's disease are amyloid β deposition and neurofibrillary tangles. In the absence of effective therapeutic drugs, alzheimer's disease places a heavy burden on both the home and society.
It is thought that microglial dysregulation may be one of the causes of Alzheimer's disease, and that selective M2 activation has the effects of secreting anti-inflammatory factors, neurotrophic factors and the like to protect nerves, while M1 classical activation M1 destroys neurons in a detrimental inflammatory response.
Therefore, starting from M2 microglial cells and secretion/exosome thereof, the preparation method is a feasible way for researching the medicines for treating the neurodegenerative diseases.
Disclosure of Invention
The application identifies peptides with therapeutic effect/auxiliary therapeutic effect on neurodegenerative diseases such as Alzheimer's disease in enzymolysis products of M2 microglial exosomes, and 3 polypeptides with therapeutic potential on Alzheimer's disease are obtained through practical D-galactose mouse model verification of oxidation resistance screening, toxicity screening and digestion screening.
In one aspect, the application provides a composition for treating a neurodegenerative disease, the composition comprising a polypeptide derived from an M2 microglial exosome, the polypeptide having the amino acid sequence of SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5.
Further, the neurodegenerative disease is Alzheimer's disease.
Further, the polypeptide is the only active ingredient in the so-called composition.
Further, the composition is in liquid form.
Further, the composition also comprises one or more auxiliary materials selected from solvents, cosolvents, pH regulators and osmotic pressure regulators.
Depending on the digestive and bioavailable properties of the polypeptide, the composition may be in liquid form, such as an injection or an oral liquid; can be in the form of oral preparation such as tablet, capsule, etc.
In another aspect, the application provides a polypeptide derived from an M2 microglial exosome, the amino acid sequence of which is SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5.
In another aspect, the application provides the use of a polypeptide derived from an M2 microglial exosome, the amino acid sequence of which is SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5, in the manufacture of a medicament for the treatment of a neurodegenerative disease.
Further, the neurodegenerative disease is Alzheimer's disease.
In another aspect, the present application provides a method for preparing the above polypeptide, which is a solid phase synthesis method.
In another aspect, the application provides a method of treating a neurodegenerative disease, such as Alzheimer's disease, comprising administering to a subject suffering from a neurodegenerative disease a polypeptide as described above.
The subject may be a human or an animal.
Due to the differences in regulations, no method of treatment of the disease is claimed in the present application, but applicants reserve the right to apply for a method of treatment based on the above description.
The polypeptide is obtained by enzymolysis and separation from human M2 microglial exosomes, and has better safety; the method has the advantages that the method shows more remarkable effects on Morris water maze test and serum GSH, SOD, A beta 1–42 level in a D-galactose mouse model. Provides a new potential drug choice for treating such diseases.
Drawings
FIG. 1 shows DPPH radical scavenging performance of 6 polypeptides;
FIG. 2 is a graph of the reducing power performance of 6 polypeptides;
FIG. 3 is a Morris water maze test result; part a is latency; the part B is the total distance;
FIG. 4 shows the results of the concentration detection of Abeta 1–42;
FIG. 5 shows the results of GSH and SOD activity assays.
Detailed Description
EXAMPLE 1 M2 preparation and enzymatic treatment of microglial exosomes
HMC3 microglial cell line was purchased from Abiowell; the cells were induced to culture M2 microglial cells (marked by increased Arg-1/Ym1 expression as observed under a microscope) using DMEM containing 20ng/mL of IL-4 according to the prior art.
Collecting exosomes of M2 microglial cells by an ultracentrifugation method; performing ultrasonic treatment and cracking; preparing into 1M (urea concentration meter) solution; adding trypsin (2%) and papain (2%) for enzymolysis, and performing enzymolysis at 37 ℃ for 1 hour; inactivating enzyme in boiling water bath, and collecting supernatant.
Example 2 identification and screening of peptides
Intercepting a fraction below 3.0kDa by using an ultrafiltration membrane; separation using semi-preparative HPLC (Ultimate 3000,3000, zemoeimeric); selecting a part with better activity by taking antioxidant activity as a basic index; analysis using LC-MS/MS (Ab Sciex Triple Quad 4500, match ACCLAIM PEPMAP C18); maxQuant the analytical peptide data was retrieved from Uniport database.
Docking and free energy analysis (peptide docking) of the obtained peptide data using BDNF as target; predicting toxicity of the peptide using admetSAR; PEPTIDERANKER predict biological activity; BIOPEP-UWM predicts gastrointestinal tract digestions (pepsin, trypsin).
The following peptides were selected by combining the above factors:
TABLE 1 preliminary screening of peptides
| Sequence and numbering | Molecular weight | Toxicity of | Gastrointestinal digestibility |
| PEVQQACSEQ ID NO.1 | 773.3 | Nontoxic | Indigestion is prevented |
| FMLHIKLSEQ ID NO.2 | 900.5 | Nontoxic | Digestion |
| EICAEGSSEQ ID NO.3 | 707.2 | Nontoxic | Indigestion is prevented |
| RNQMVWSEQ ID NO.4 | 832.4 | Nontoxic | Indigestion is prevented |
| SSCFNYSEQ ID NO.5 | 719.2 | Nontoxic | Digestion |
| LVPSESEQ ID NO.6 | 543.2 | Nontoxic | Indigestion is prevented |
EXAMPLE 3 detection of antioxidant Properties of peptides
The 6 polypeptides were subjected to solid-phase synthesis by the client gold, and DPPH radical scavenging rate and reducing power were measured:
DPPH radical scavenging Rate determination:
Preparing a polypeptide solution sample according to the concentration of 0.05 mg/mL; taking 2mL of a sample, mixing with 2mL of a DPPH absolute ethanol solution (sample) with the concentration of 0.1mM or 2mL of absolute ethanol (control), and carrying out light-shielding reaction for 30min at the temperature of 25 ℃; measuring absorbance at 517nm of the sample reaction solution, the control reaction solution and a reference (2 mL of absolute ethyl alcohol plus 2mL of 0.1mM DPPH absolute ethyl alcohol solution) by using a spectrophotometer; DPPH radical clearance% = (1- (a Sample of -A Control ）/A Reference(s) ) x 100%.
Reducing force measurement:
Preparing a polypeptide solution sample according to the concentration of 0.05 mg/mL; taking 2mL of a sample, and mixing with 2mL of 1% potassium ferricyanide aqueous solution and 3mL of PBS with pH of 6.5; reacting at 45 ℃ for half an hour; 2mL of a 10% by mass trichloroacetic acid solution was added; centrifuging for 10min; 2mL of the supernatant was mixed with 2mL of distilled water and 0.1% by mass of an aqueous solution of ferric chloride, and the reducing power was directly expressed as absorbance A 700 at 700 nm.
The results are shown in figures 1 and 2, and SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5 and SEQ ID NO.6 with good selection effect are used for further animal model tests.
EXAMPLE 4 Effect in D-galactose Alzheimer's disease mouse model
22 G.+ -.2 g of healthy Kunming mice 60 were divided equally into 6 groups:
Positive control group: d-gal 8mg was subcutaneously injected daily for 6 weeks;
A negative control group, daily subcutaneous saline, for 6 weeks;
Sequence 1 group, daily subcutaneous injection of D-gal 8mg, for 6 weeks; from day 8 (day 1 when D-gal injection was started), 20mg of the SEQ ID NO.1 polypeptide was infused daily;
Sequence 3 groups, daily subcutaneous injections of D-gal 8mg, for 6 weeks; from day 8 (day 1 when D-gal injection was started), 20mg of the polypeptide SEQ ID NO.3 was infused daily;
sequence 5 groups, daily subcutaneous injections of D-gal 8mg, for 6 weeks; from day 8 (day 1 when D-gal injection was started), 20mg of the SEQ ID NO.5 polypeptide was infused daily;
Sequence 6 groups, daily subcutaneous injections of D-gal 8mg, for 6 weeks; from day 8 (day 1 when D-gal injection was started), 20mg of the SEQ ID NO.6 polypeptide was infused daily.
After the injection period, mice were subjected to Morris water maze test to detect GSH, SOD level, abeta 1–42 (Van-state biological mouse GSH ELISA kit, pullulan SOD activity kit, kang Lang biological mouse Abeta 1–42 ELISA kit) in serum.
As with the computer predicted results, the mice did not die or have obvious toxic symptoms (body weight, degree celsius, activity, skin and basic blood biochemical indicators were all substantially normal) during the test.
The experimental results are shown in fig. 3-5, compared with the negative control group, the latency time and the total distance after the positive control group induces aging are obviously longer, abeta 1–42 has an enrichment trend, GSH and SOD levels are reduced, and the model successfully simulates the neural aging symptoms of the Alzheimer disease. The polypeptides of SEQ ID No.1, SEQ ID No.3 and SEQ ID No.5 effectively reduce the symptoms, and SEQ ID No.6 has no obvious effect in most indexes.
Claims (9)
1. A composition for use in the treatment of a neurodegenerative disease, comprising a polypeptide derived from an M2 microglial exosome having the amino acid sequence SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5.
2. The composition of claim 1, wherein the neurodegenerative disease is alzheimer's disease.
3. The composition according to claim 1 or 2, wherein the polypeptide is the sole active ingredient in a so-called composition.
4. A composition according to claim 3, wherein the composition is in liquid form.
5. The composition of claim 4, wherein the composition further comprises one or more adjuvant ingredients selected from the group consisting of solvents, co-solvents, pH modifiers, osmolality modifiers.
6. A polypeptide derived from M2 microglial exosomes, characterized in that the amino acid sequence of the polypeptide is SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5.
7. Use of a polypeptide derived from M2 microglial exosomes in the preparation of a medicament for the treatment of neurodegenerative diseases, the amino acid sequence of the polypeptide being SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5.
8. The use according to claim 7, wherein the neurodegenerative disease is alzheimer's disease.
9. A method of preparing a polypeptide according to claim 6, wherein the method is a solid phase synthesis method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410424222.XA CN118001370A (en) | 2024-04-10 | 2024-04-10 | Compositions and methods for treating neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410424222.XA CN118001370A (en) | 2024-04-10 | 2024-04-10 | Compositions and methods for treating neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118001370A true CN118001370A (en) | 2024-05-10 |
Family
ID=90950429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410424222.XA Pending CN118001370A (en) | 2024-04-10 | 2024-04-10 | Compositions and methods for treating neurodegenerative diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118001370A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307391A1 (en) * | 2015-06-12 | 2018-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| CN112194730A (en) * | 2020-10-28 | 2021-01-08 | 中国医科大学 | Polypeptide TI-16 and application thereof |
| CN113057963A (en) * | 2021-03-31 | 2021-07-02 | 华中科技大学 | Specific capture carrier for eliminating beta-amyloid and application thereof |
| CN117126243A (en) * | 2023-10-26 | 2023-11-28 | 中国海洋大学 | Small molecular peptide PYPDW and application thereof |
| CN117683843A (en) * | 2023-12-13 | 2024-03-12 | 浙江省农业科学院 | Hickory nut polypeptide for relieving or improving Alzheimer's disease and application thereof |
-
2024
- 2024-04-10 CN CN202410424222.XA patent/CN118001370A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307391A1 (en) * | 2015-06-12 | 2018-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| CN112194730A (en) * | 2020-10-28 | 2021-01-08 | 中国医科大学 | Polypeptide TI-16 and application thereof |
| CN113057963A (en) * | 2021-03-31 | 2021-07-02 | 华中科技大学 | Specific capture carrier for eliminating beta-amyloid and application thereof |
| CN117126243A (en) * | 2023-10-26 | 2023-11-28 | 中国海洋大学 | Small molecular peptide PYPDW and application thereof |
| CN117683843A (en) * | 2023-12-13 | 2024-03-12 | 浙江省农业科学院 | Hickory nut polypeptide for relieving or improving Alzheimer's disease and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| GUO, JD等: ""Effects of velvet antler polypeptides on Alzheimer\'s disease cell model via miR-613 / HDAC6 pathway"", 《PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 33, no. 3, 31 May 2020 (2020-05-31), pages 1427 - 1433 * |
| 陈学军;徐建富;李丽琴;石童;张奇志;: "蛋白多肽类药物脑靶向给药策略研究进展", 解放军药学学报, no. 06, 20 December 2015 (2015-12-20), pages 88 - 92 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003137807A (en) | Collagen-producing promoter, cosmetic, food and pharmaceutical containing the same and external preparation for preventing or improving dermatosis | |
| CN1328285C (en) | Inhibitor of stem cell proliferation and uses thereof | |
| US20050037430A1 (en) | Methods and uses for protein breakdown products | |
| TWI588153B (en) | Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides | |
| US20090227505A1 (en) | Methods and uses for protein breakdown products | |
| CN101048170B (en) | Analgesic peptide like compounds stemed from rattlesnake crotalus durissus terrificus snake wenom, their application, compositions, preparation and purification method | |
| JP6430938B2 (en) | Synthetic polypeptide PnTx (19), pharmaceutical composition and use thereof | |
| CN118001370A (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP4209500A1 (en) | Peptide, and cosmetic composition and pharmaceutical composition comprising same | |
| CN113491763B (en) | Application of cobra neurotoxin and preparation thereof in preparation of medicine for preventing and/or treating parkinsonism | |
| KR102174194B1 (en) | Composition for preventing, treating and improving atopic dermatitis comprising flavanone-resveratrol conjugate | |
| CN108715601B (en) | Polypeptide with antioxidant and Abeta 42 aggregation inhibiting properties, application thereof and gene for encoding polypeptide | |
| CN110038116B (en) | Application of human liver secretory protein GPNMB or antagonist or agonist thereof | |
| KR20060126419A (en) | Atopic dermatitis inducer | |
| EP0382720B1 (en) | Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity | |
| Talme et al. | Somatostatin-and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calcipotriol treatment | |
| JP3445593B2 (en) | Peptides and their uses | |
| US11571462B2 (en) | Engineered CCL20 locked dimer polypeptide | |
| Mei et al. | The effect of curcumin on Aβ, Akt, and GSK3β on the brain and retina of APP/PS1 mice and in the blood of alzheimer's patients with early-stage disease | |
| CN106478811A (en) | Mercuric chloride protease inhibitory peptides and its gene and the application in pharmacy | |
| JP4044842B2 (en) | Screening method for drugs that can treat obesity | |
| KR20070117889A (en) | A pharmaceutical composition comprising the extract of artemisa spp for treating or preventing inflammatory bowel disease | |
| Chornenka et al. | Molecular Genetic and Cytological Features of Healing in Esophageal Alkaline Burns and When Melanin is Administered | |
| Li et al. | Newly identified peptide Nigrocin-OA27 inhibits UVB induced melanin production via the MITF/TYR pathway | |
| CA2151059A1 (en) | Cathepsin-l-specific inhibitor polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |